Combination use of insulin and incretins in type 2 diabetes
The objective of this review was to summarize and critically appraise the evidence regarding the clinical effectiveness and harms of combination use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogues with insulin. The following research questions were assessed:...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
[2013], 2013
|
Series: | CADTH optimal use report
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review was to summarize and critically appraise the evidence regarding the clinical effectiveness and harms of combination use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogues with insulin. The following research questions were assessed: 1. What is the clinical efficacy and safety of DPP-4 inhibitors used in combination with insulin for patients with inadequate glycemic control on a basal or biphasic insulin regimen? 2. What is the clinical efficacy and safety of GLP-1 analogues used in combination with insulin for patients with inadequate glycemic control on a basal or biphasic insulin regimen? |
---|---|
Item Description: | "July 2013." |
Physical Description: | 1 PDF file (ii, 18 pages) illustrations |